The efficacy and safety of weekly semaglutide (2.4 mg) for the treatment of overweight and obesity was investigated in the Semaglutide Treatment Effect in People with Obesity (STEP) programme, which included individuals with overweight (BMI 27 kg/m 2 ) and complications, including dyslipidaemia, hypertension, sleep apnoea, cardiovascular disease and type 2 diabetes, or individuals with obesity (BMI 30 kg/m 2 ) with or without complications [26, 34,35,36,37,38,39]
A decrease in inflammatory intestinal markers following BPC-157 administration has been associated with improvements in conditions such as fistulas and short bowel syndrome
Medication Management and Monitoring Patients may need to adjust their dosages or administration schedules when transitioning to Retatrutide, and they should be mindful of any potential side effects or interactions with their existing medications
HRT Bio-identical hormone replacement therapy
Bevestig dit voordat u een bestelling plaatst